Yukinobu; Chen, Feng; Egawa, Hiroto Elsevier B.V.; この論文は出版社版でありま Right. 引用の際には出版社版をご確認ご利用ください This is
|
|
- Erika Benson
- 5 years ago
- Views:
Transcription
1 Title Does a positive lymphocyte cross-ma donor liver transplantation? Hori, Tomohide; Uemoto, Shinji; Tak Author(s) Fumitaka; Ogura, Yasuhiro; Ogawa, K Hayashino, Aya; Yurugi, Kimiko; Ngu Yukinobu; Chen, Feng; Egawa, Hiroto Citation Surgery (2010), 147(6): Issue Date URL Elsevier B.V.; この論文は出版社版でありま Right 引用の際には出版社版をご確認ご利用ください This is not the published version. Please c version. Type Journal Article Textversion author Kyoto University
2 Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Tomohide Hori, MD, PhD, a,b Shinji Uemoto, MD, PhD, a Yasutsugu Takada, MD, PhD, a Fumitaka Oike, MD, PhD, a Yasuhiro Ogura, MD, PhD, a Kohei Ogawa, MD, PhD, a Aya Miyagawa-Hayashino, MD, PhD, c Kimiko Yurugi, PhD, d Justin H. Nguyen, MD, PhD, b Feng Chen, PhD, b Yukinobu Hori, LLM, c Hiroto Egawa, MD, PhD a a Department of Transplant Surgery, c Department of Diagnostic Pathology and d Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, , Japan. b Department of Transplant Surgery, Mayo Clinic, FL 32224, USA. c Nagoya Economic University Graduate School of Law, Aichi Prefecture, , Japan Corresponding author: Tomohide Hori, Ph.D., M.D. Department of Transplant Surgery, Kyoto University Hospital, 54 Shogoinkawara-cho, Sakyo-ku, Kyoto , Japan Phone: ,; FAX: ,; horit@kuhp.kyoto-u.ac.jp 1
3 Abstract Background. There is still no consensus on the importance of lymphocyte cross-matching (LCM) in the field of living-donor liver transplantation (LDLT). Methods. LCM examinations are routinely performed before LDLT, and the results of complement-dependent cytotoxicity were used in this study. A total of 1157 LDLT cases were evaluated. The recipients were divided into four groups based on the LCM and ABO compatibilities: (i) negative LCM and identical/compatible ABO; (ii) negative LCM and incompatible ABO; (iii) positive LCM and identical/compatible ABO; and (iv) positive LCM and incompatible ABO. The diagnosis of antibody-mediated rejection (AMR) was made based on the clinical course, immunological assays and histopathological findings. C4d immunostaining was added if AMR was suspected. Results. The LCM-positive LDLT recipients showed significantly poorer outcomes than the LCM-negative recipients. Among the LCM-positive recipients, 44.1% of recipients eventually died and 85.2% of recipients revealed positive C4d findings. The survival rate of LCM-positive and ABO-incompatible group was The survival days were compared with the LCM-negative and ABO-identical/compatible group, and the LCM-positive and ABO-identical/compatible group clearly showed early death after LDLT, although the ABO-incompatible groups did not show significant. The factors of age, disease, pre-transplant scores, LCM, ABO compatibility and graft-recipient weight ratio showed statistical significance in multivariate analysis for important 2
4 factors of LDLT outcomes. However, the LCM and ABO compatibilities had no synergetic effects on the LDLT survival. Conclusion. HLA antigens are more widely expressed than ABO antigens, and advanced immunological strategies must be established for LCM-positive LDLT as well as for ABO-incompatible LDLT. 3
5 Introduction The impacts of lymphocyte cross-matching (LCM) and human leukocyte antigen (HLA) histocompatibility have been reported for organ transplantation. 1-4 Antibody-mediated rejection (AMR) is still a serious problem after organ transplantation, 5,6 although liver transplantation (LT) involving a positive LCM combination between donor and recipient is rare, even under donor shortage. Within the LT field, it is generally believed that positive LCM does not contraindicate LT, because many contradictory reports have been published. 3,4,7-9 Some investigators have suggested the importance of appropriate LCM while others have concluded that positive LCM has no impact on LT outcomes. 3,4,7-9 In the transplant immunity field, several investigators have indicated that HLA histocompatibility has dualistic effects (reduction of rejection incidence and enhancement of allograft dysfunction) in liver allografts. 8 Therefore, there is still no consensus on the importance of LCM in the LT field. This study focused the effects of positive LCM on living donor LT (LDLT) outcomes. Patients and Methods LCM examinations (complement-dependent cytotoxicity (CDC) and anti-human globulin assays) are routinely performed before LDLT in Kyoto University Hospital. The results of direct CDC assays, which were performed to detect anti-donor antibodies 10, were used in this study. 4
6 Briefly, 1 µl of donor lymphocyte suspension and 5 µl of recipient serum, which was obtained before LDLT, were incubated in a Terasaki plate (Nunc, Roskilde, Denmark) at room temperature for 30 min. Next, 5 µl of rabbit complement was added to each well, and the mixtures were incubated at room temperature for 60 min. After the addition of 2 µl of 5% eosin solution, the cells were fixed with formalin. The plate was examined by phase-contrast microscopy (IMT-2; Olympus, Tokyo, Japan). The results were considered positive when more than 20% of the donor lymphocytes were killed by the recipient's serum. 10 A total of 1157 LDLT cases during 13.5 years (485 pediatric and 672 adult recipients from January 1996 to June 2009) were evaluated. The clinical courses of all the recipients were followed for ± days (range, 2 (dead case) to 5041 days) after LDLT. The immunosuppressive regimens including those for ABO incompatibility were described in detail elsewhere. 11,12 The recipients were divided into four groups based on the LCM and ABO compatibilities: (i) negative LCM and identical/compatible ABO (n=952; 399 pediatric and 553 adult recipients); (ii) negative LCM and incompatible ABO (n=171; 74 pediatric and 97 adult recipients); (iii) positive LCM and identical/compatible ABO (n=30; 11 pediatric and 19 adult recipients); and (iv) positive LCM and incompatible ABO (n=4; 1 pediatric and 3 adult recipients). All positive LCM cases showed the immunoreactivity against HLA Class I antigens in this study. The diagnosis of AMR was made based on the clinical course, immunological assays and histopathological findings. C4d immunostaining was added if AMR was suspected. 4 Regarding the methodology for C4d immunostaining, our procedures including the evaluation and control 5
7 materials were described in detail elsewhere. 13,14 Briefly, portal stromal or endothelial staining was considered to be positive to minimize false-positives. 13,14 Univariate and multivariate analyses were used for between-group comparisons of LDLT outcomes as follows: Mann-Whitney U test for early death; Kaplan-Meier method (log-rank) for the survival rates; logistic regression analysis for important factors predicting outcomes; and multiple analysis of covariance for the effects and synergetic effects of the factors on the survival rates. All the calculations were performed using SSPS-II (SSPS Japan, Tokyo, Japan). Values of p<0.05 were considered to indicate statistical significance. Results The LCM-positive LDLT recipients (n=34) showed significantly poorer outcomes than the LCM-negative recipients (n=1123) (p<0.0001). Among the LCM-positive recipients, four received re-ldlt owing to graft loss. Fifteen recipients eventually died (44.1%) because of AMR or chronic rejection (9 cases), portal or hepatic arterial thrombosis (3 cases) and sepsis (3 cases). C4d staining was performed in 27 cases and revealed positive findings in 23 cases (85.2%). Portal endothelial immunostaining was the most common staining pattern, and this staining was observed in all 23 cases. Portal stromal immunostaining was positive in 12 cases. The survival curves of each group are shown in Fig. 1. Four patients were LCM-positive and ABO-incompatible. Three of these four patients received histopathological examinations and 6
8 were positive for C4d staining (one endothelial and two stromal immunostaining patterns). Two of the four patients finally died, while one patient recovered after re-transplantation. Therefore, the survival rate of this group was The LCM-positive recipients seemed to die earlier than the LCM-negative recipients (Fig. 1). Therefore, the survival days for the dead cases in each group were compared with the LCM-negative and ABO-identical/compatible group (Table 1). Although the ABO-incompatible groups did not show significant differences, the LCM-positive and ABO-identical/compatible group clearly showed early death after LDLT. Previous studies have documented the important factors for LT outcomes, such as recipient age, disease, donor age, scores of model for end-stage liver disease (MELD) or pediatric end-stage liver disease (PELD), ABO incompatibility, cold ischemic time, operative time, blood loss and graft-recipient weight ratio (GRWR). 11,15-22 To investigate which factors are important for LDLT outcomes, multivariate analyses were performed (Table 1). The factors of age, disease, MELD/PELD scores, LCM, ABO compatibility and GRWR showed statistical significance. To investigate the effects of LCM and ABO compatibilities and the synergetic effects of these factors on LDLT survival, multivariate analyses were performed in 1121 recipients who were followed for at least 1 year and dead cases (Table 1). The LCM and ABO compatibilities each had significant effects on the LDLT survival. However, they had no synergetic effects on the LDLT survival. 7
9 Discussion The LDLT recipients with positive LCM showed the poorest outcomes in their survival curve and the most drastic postoperative courses, even compared with the ABO-incompatible cases. Possible explanations for these findings are as follows: (i) HLA antigens are more widely expressed than ABO antigens; (ii) ABO-incompatible recipients have recently achieved excellent results similar to ABO-identical/compatible cases using established strategies, although the overall survival of the ABO-incompatible cases still showed a significant difference compared with that of the ABO-identical/compatible cases; and (iii) LCM-positive recipients still do not receive any treatments to prevent AMR occurrence (i.e., they receive usual immunosuppression after LDLT and no specialized preconditioning before LDLT). There have been many contradictory reports regarding importance of HLA compatibility in LT. 7-9 Some investigators have suggested that HLA histocompatibility for Class I is crucial for graft survival after LT while others have documented that there may be a dualistic effect of HLA histocompatibility in liver allografts. They suggested that although HLA histocompatibility reduced the incidence of rejection, it may also enhance other immunologic mechanisms which can lead to allograft dysfunction. Our results advocated the previous opinion that HLA histocompatibility for Class I is important for LT outcomes. Previous studies have reported that several factors are crucial for LT outcomes, 11,15-22 and that LDLT outcomes are excellent especially in pediatric recipients. 16,23 The overall outcomes in pediatric LDLT are also excellent compared with adult LDLT in our institution. The results of our 8
10 multivariate analyses, which revealed the importance of age, disease and GRWR, are easy to understand from the viewpoints of previous opinions and pediatric outcomes. The importance of the MELD/PELD scores and ABO incompatibility is also consistent with previous reports. However, LCM also had a large impact on the LDLT outcomes in this study. We previously reported that standard therapies during and after LDLT (i.e., plasma exchange, 24 high-dose immunoglobulins 25 and splenectomy 26 ) have limited use as AMR treatments and that strong immunosuppression is needed to maintain a negative LCM after LDLT. 27 Moreover, we hypothesized that preoperative induction therapy to prevent AMR may confer a large advantage similar to the case for ABO incompatibility, because LDLT leaves more time for immunological examinations and the induction of suitable preconditions compared with deceased donor LT. Furthermore, we suggested that stronger immunosuppression is required for positive LCM than for ABO-incompatible cases, because HLA antigens are more widely expressed than ABO antigens. Hence, modified regimens based on our regimen for conquering ABO incompatibility are considered to be suitable strategies for LCM-positive LDLT, and we have already initiated a prospective study including monitoring methods. Since LCM influences are considered to be debatable in LT, including deceased donor LT, many transplant centers in the United States and Europe skip cross-mach tests before LDLT or only investigate LCM retrospectively, for cost-saving reasons. 27 We have clearly demonstrated that positive LCM has a fatal impact on LDLT. Since not all of our positive LCM cases died, we suggest that positive LCM itself does not contraindicate LDLT. However, we conclude that advanced 9
11 immunological strategies must be established for LCM-positive LDLT as well as for ABO-incompatible LDLT. 10
12 References 1. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: Piazza A, Poggi E, Borrelli L, Servetti S, Monaco PI, Buonomo O, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: Muro M, Marin L, Miras M, Moya-Quiles R, Minguela A, Sanchez-Bueno F, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: Sugawara Y, Makuuchi M, Kaneko J, Saiura A, Imamura H, Kokudo N. Risk factors for acute rejection in living donor liver transplantation. Clin Transplant 2003; 17: Padmanabhan A, Ratner LE, Jhang JS, Duong JK, Markowitz GS, Vasilescu ER, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation 2009; 87: Leffell MS, Zachary AA. The role of the histocompatibility laboratory in desensitization for transplantation. Curr Opin Organ Transplant 2009; 14: Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, et al. 11
13 Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation 1988; 46: Donaldson P, Underhill J, Doherty D, Hayllar K, Calne R, Tan KC, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "the dualistic effect". Hepatology 1993; 17: Nikaein A, Backman L, Jennings L, Levy MF, Goldstein R, Gonwa T, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58: Ashihara E, Tsuji H, Sakashita H, Haga H, Yurugi K, Kimura S, et al. Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants: effect on survival. Transplantation 2007; 83: Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47: Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K, Oike F, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005; 37: Haga H, Egawa H, Fujimoto Y, Ueda M, Miyagawa-Hayashino A, Sakurai T, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: Sakashita H, Haga H, Ashihara E, Wen MC, Tsuji H, Miyagawa-Hayashino A, et al. 12
14 Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: Austin GL, Sasaki AW, Zaman A, Rabkin JM, Olyaei A, Ruimy R, et al. Comparative analysis of outcome following liver transplantation in US veterans. Am J Transplant 2004; 4: Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: Park JB, Kwon CH, Choi GS, Chun JM, Jung GO, Kim SJ, et al. Prolonged cold ischemic time is a risk factor for biliary strictures in duct-to-duct biliary reconstruction in living donor liver transplantation. Transplantation 2008; 86: Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: Mor E, Jennings L, Gonwa TA, Holman MJ, Gibbs J, Solomon H, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993; 176: Ben-Haim M, Emre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, et al. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 2001; 7: Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 13
15 39: Rhee C, Narsinh K, Venick RS, Molina RA, Nga V, Engelhardt R, et al. Predictors of clinical outcome in children undergoing orthotopic liver transplantation for acute and chronic liver disease. Liver Transpl 2006; 12: Cacciarelli TV, So SK, Egawa H, Cox K, Esquivel CO. Impact of reduced-size liver transplantation on rejection and liver allograft outcome in the pediatric population. Transplant Proc 1995; 27: Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83: Hori T, Egawa H, Takada Y, Oike F, Ogura Y, Ogawa K, Kaido T, Toshimitsu Y, Yagi S, Iida T, Nguyen JH, Uemoto S. Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. Transpl Int 2009 (Epub ahead). 14
16 Figure legend Fig.1 The survival curves of each group after LDLT 15
Antibody-mediated rejection after adult living-donor liver transplantation triggered by positive lymphocyte cross-match combination
CASE REPORT Annals of Gastroenterology (2012) 25, 66-72 Antibody-mediated rejection after adult living-donor liver transplantation triggered by positive lymphocyte cross-match combination Tomohide Hori,
More informationORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationIn-Hospital Mortality in Adult Recipients of Living Donor Liver Transplantation: Experience of 576 Consecutive Cases at a Single Center
LIVER TRANSPLANTATION 15:1420-1425, 2009 ORIGINAL ARTICLE In-Hospital Mortality in Adult Recipients of Living Donor Liver Transplantation: Experience of 576 Consecutive Cases at a Single Center Toshimi
More informationElsevier B.V.; この論文は出版社版でありま Right 引用の際には出版社版をご確認ご利用ください This is
Title Refractory cutaneous lichenoid sarc tranilast. Author(s) Nakahigashi, Kyoko; Kabashima, Kenj Utani, Atsushi; Miyachi, Yoshiki Citation Journal of the American Academy of 63(1): 171-172 Issue Date
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More information--Manuscript Draft-- living donor liver transplantation; lymphocytotoxicity crossmatch; rituximab. Dokkyo Medical University mibucho, Tochigi JAPAN
International Surgery Living donor liver transplantation in a highly allo-sensitized recipient: confusing influence of rituximab on the lymphocytotoxicity crossmatch test; a case report --Manuscript Draft--
More informationErratum to: Int J Hematol (2014) 99: DOI /s
Int J Hematol (216) 13:725 729 DOI 1.17/s12185-16-1987-1 ERRATUM Erratum to: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history
More informationEffect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/1.4174/astr.215.88.2.1 Annals of Surgical Treatment and Research Effect of donor-specific antibodies and panel reactive antibodies in
More informationQuantitative Survival Model for Short-Term Survival After Adult-to-Adult Living Donor Liver Transplantation
LIVER TRANSPLANTATION 12:904-911, 2006 ORIGINAL ARTICLE Quantitative Survival Model for Short-Term Survival After Adult-to-Adult Living Donor Liver Transplantation Ichiro Tsunematsu, 1 3 Yasuhiro Ogura,
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationこの論文は出版社版でありません 引用の際には出版社版をご確認ご利用ください This is not the publis version. Please cite only the publi
Title A case of progressive digital ische gemcitabine and S-1 in a patient wi Zaima, C; Kanai, M; Ishikawa, S; Ka Author(s) Mori, Y; Nishimura, T; Matsumoto, S T; Mimori, T Citation Japanese journal of
More informationImpact of Rituximab Desensitization on Blood-Type-Incompatible Adult Living Donor Liver Transplantation: A Japanese Multicenter Study
Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12520 Impact of Rituximab Desensitization on Blood-Type-Incompatible
More informationApplication of Complement Component TitleImmunohistochemistry to ABO-Compati.
Application of Complement Component TitleImmunohistochemistry to ABO-Compati Incompatible Liver Transplantation( Author(s) Salah, Adeeb Ahmed Kassim Citation Kyoto University ( 京都大学 ) Issue Date 2015-03-23
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationFeasible usage of ABO incompatible grafts in living donor liver transplantation
Original Article Feasible usage of ABO incompatible grafts in living donor liver transplantation Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara Department
More informationABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR
ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....
More informationDonor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative Renal Transplants
Available online at www.annclinlabsci.org 330 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Donor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationDonor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation
8 Original Article Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation Neema Kaseje 1 Samuel Lüthold 2 Gilles Mentha 3 Christian Toso 3 Dominique Belli 2 Valérie McLin 2 Barbara
More informationPostoperative Hyperbilirubinemia and Graft Outcome in Living Donor Liver Transplantation
LIVER TRANSPLANTATION 13:1538-1544, 2007 ORIGINAL ARTICLE Postoperative Hyperbilirubinemia and Graft Outcome in Living Donor Liver Transplantation Shigeru Marubashi, Keizo Dono, Hiroaki Nagano, Tadafumi
More informationLiver transplantation (LT) across the ABO bloodtype. Present Status of ABO-Incompatible Living Donor Liver Transplantation in Japan
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Present Status of ABO-Incompatible Living Donor Liver Transplantation in Japan Hiroto Egawa, 1 Satoshi Teramukai, 2 Hironori Haga, 1 Minoru Tanabe, 1 Masanori
More informationPortal Pressure <15 mm Hg Is a Key for Successful Adult Living Donor Liver Transplantation Utilizing Smaller Grafts than Before
LIVER TRANSPLANTATION 16:718-728, 2010 ORIGINAL ARTICLE Portal Pressure
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationLong-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary Cirrhosis: A Japanese Multicenter Study
American Journal of Transplantation 2016; 16: 1248 1257 Wiley Periodicals Inc. Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13583
More informationOutcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis
Submit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i35.6516 World J Gastroenterol 2017 September 21; 23(35): 6516-6533 ISSN 1007-9327 (print) ISSN 2219-2840 (online) META-ANALYSIS Outcomes
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationExtending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationSurvival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation
American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationLive Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease
Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease Abhi Humar, MD Clinical Director, Thomas E. Starzl Transplantation Institute 1 PITTSBURGH THE BIRTHPLACE OF LIVER TRANSPLANTATION
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationCitation Journal of Cardiology Cases (2013), Ltd.; この論文は出版社版でありません 引用の際には出版社版をご確認ご利用ください This is not the publ
Title Pathological analyses of very longimplantation in human coronary arte Author(s) Imai, Masao; Kimura, Takeshi; Tazak Erika; Inoue, Katsumi Citation Journal of Cardiology Cases (01), Issue Date 01-
More informationAntihuman leukocyte antigen (HLA) antibodies can be
Antihuman Leukocyte Antigen Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches Ibrahim Batal, MD; Adriana Zeevi, PhD; John
More informationUEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationLiving donor liver transplantation for patients with hepatocellular carcinoma in Japan
Sugawara et al. Hepatoma Res 2018;4:33 DOI: 10.20517/2394-5079.2018.69 Hepatoma Research Review Open Access Living donor liver transplantation for patients with hepatocellular carcinoma in Japan Yasuhiko
More informationInformation for patients (and their families) waiting for liver transplantation
Information for patients (and their families) waiting for liver transplantation Waiting list? What is liver transplant? Postoperative conditions? Ver.: 5/2017 1 What is a liver transplant? Liver transplantation
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More information- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ.
Immunology Lecture num. (21) Transplantation - Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ. Types of Graft (4 types): Auto Graft - From a person
More informationHLA HISTOCOMPATIBILITY AND LIVER TRANSPLANT SURVIVAL
HLA HISTOCOMPATIBILITY AND LIVER TRANSPLANT SURVIVAL Bernd H. Markus*, John J. Fung, Robert D. Gordon, Marian Vanek, Thomas E. Starzl, and Rene J. Duquesnoy From the Department of Surgery and the Division
More informationLong-term Outcomes After Third Liver Transplant
ArtıcLe Long-term Outcomes After Third Liver Transplant C. Burcin Taner, 1 Deniz Balci, 1 Darrin L. Willingham, 1 Andrew P. Keaveny, 1 Barry G. Rosser, 1 Juan M. Canabal, 1 Timothy S. J. Shine, 2 Denise
More informationXM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU
Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89
More informationHong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver
Hong Kong Journal Nephrol of 2000;(2):79-83. Nephrology 2000;2(2):79-83. ORIGINAL A R T I C L E A point score system for allocating cadaveric kidneys for transplantation based on patient age, waiting time
More informationPediatric Liver Transplantation Outcomes in Korea
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon
More informationORIGINAL ARTICLE. Underlying Disease as a Predictor for Rejection After Liver Transplantation
ORIGINAL ARTICLE Underlying Disease as a Predictor for Rejection After Liver Transplantation Gabriela A. Berlakovich, MD; Susanne Rockenschaub, MD; Susanne Taucher, MD; Klaus Kaserer, MD; Ferdinand Mühlbacher,
More informationNo evidence of C4d association with AMR However, C3d and AMR correlated well
C4d positivity Poor prognostic factor Reversal to C4d negativity did not change prognosis, with current therapy Prognostic factor for CAV Variable time line for CAV/death No correlation with cellular rejection
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationPortal Vein Thrombosis and Outcomes for Pediatric Liver Transplant Candidates and Recipients in the United States
LIVER TRANSPLANTATION 17:1066-1072, 2011 ORIGINAL ARTICLE Portal Vein Thrombosis and Outcomes for Pediatric Liver Transplant Candidates and Recipients in the United States Seth A. Waits, 1 Brandon M. Wojcik,
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationCitation Congenital Anomalies (2016), 56(2): version. この論文は出版社版でありません 引用の際には出版社版をご確認ご利用ください
Title Correlation of external ear human embryos auricle Author(s) Ozeki-Sato, Maimi; Yamada, Shigehit Ishizu, Koichi; Takakuwa, Tetsuya Citation Congenital Anomalies (2016), 56(2): Issue Date 2016-03 URL
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationThe Acceptable Mismatch program of Eurotransplant.
The Acceptable Mismatch program of Eurotransplant. Frans Claas Leiden University Medical Center Eurotransplant Reference Laboratory Leiden, the Netherlands. Hinterzarten, December 7, 2013 Main problem
More informationLiving donor liver transplantation: Eastern experiences
Living donor liver transplantation: Eastern experiences K Tanaka 1, Y Ogura 1, T Kiuchi 1, Y Inomata 2, S Uemoto 3 and H Furukawa 4 "Deportment of Transplantation and Immunology, Kyoto University Hospital,
More informationImpact Of Reconstructing A Single Hepatic Artery On Small-For-Size Grafts In Living Donor Liver Transplantation
ISPUB.COM The Internet Journal of Surgery Volume 31 Number 2 Impact Of Reconstructing A Single Hepatic Artery On Small-For-Size Grafts In Living Donor Liver K, A, B, C Citation K, A, B, C.. The Internet
More informationDebate: HLA matching matters in children
Annual Congress 2018 14 th to 16 th March, the Brighton Centre, Brighton Debate: HLA matching matters in children Presenting the case for - Dr Jon Jin (JJ) Kim, Nottingham Richard & Ronald Herrick 23 Dec
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationILTS Travel Scholar 2010
ILTS Travel Scholar 2010 Final Report Name of Scholar: Dr. Vikram NamdevRaut Name of Mentor: Dr.Yasuhiro Ogura and Professor Shinji Uemoto Institution: Department of HPB and Transplant Surgery, Graduate
More informationAMR in Liver Transplantation: Incidence
AMR in Liver Transplantation: Incidence Primary AMR 1/3 to 1/2 of ABO-incompatible transplants Uncommon with ABO-compatible transplant Secondary AMR Unknown incidence: rarely tested Why is AMR uncommon
More informationVirtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
More informationIntroduction. M. Kasahara 1, *, K. Umeshita 2, Y. Inomata 3, S. Uemoto 4 and Japanese Liver Transplantation Society
American Journal of Transplantation 2013; 13: 1830 1839 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1002/ajt.12276
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationIn the past 15 years the number of kidney
The Role of ABO-Incompatible Living Donors in Kidney Transplantation: State of the Art James Thielke, PharmD,* Bruce Kaplan, MD, and Enrico Benedetti, MD, FACS Summary: In the past, ABO incompatibility
More informationLiving donor liver transplantation (LDLT) is a
Original Article / Transplantation Hepatobiliary & Pancreatic Diseases International Graft-to-recipient weight ratio lower to 0.7% is safe without portal pressure modulation in right-lobe living donor
More information23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)
Renal transplantation Panel Reactive Antibodies and Crossmatch by Flow Cytometry Katherina Psarra Immunology Histocompatibility Dept Evangelismos Hospital Athens, Greece In spite of the enormous progress
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationPosttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationAuthor(s) Takemoto, Mitsuru; Nakamura, Takash. Citation Skeletal radiology (2011), 40(12):
Title Paraarticular osteochondroma of a c presenting as myelopathy. Author(s) Okamoto, Takeshi; Neo, Masashi; Fuj Takemoto, Mitsuru; Nakamura, Takash Citation Skeletal radiology (0), 0(): Issue Date 0-
More informationLiving Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor
Showa Univ J Med Sci 29 1, 9 15, March 2017 Original Living Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor Shinji IRIE Abstract :
More informationKidney Transplantation in Sensitized Recipients; A Single Center Experience
J Korean Med Sci 2009; 24 (Suppl 1): S143-7 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.S1.S143 Copyright The Korean Academy of Medical Sciences Kidney Transplantation in Sensitized Recipients; A Single Center
More informationAcute Humoral Rejection and C4d Immunostaining in ABO Blood Type- Incompatible Liver Transplantation
LIVER TRANSPLANTATION 12:457-464, 2006 ORIGINAL ARTICLE Acute Humoral Rejection and C4d Immunostaining in ABO Blood Type- Incompatible Liver Transplantation Hironori Haga, 1,2 Hiroto Egawa, 2 Yasuhiro
More informationEven in this era of efficient immunosuppression, a positive
OVERVIEW Enhanced Kidney Allocation to Highly Sensitized Patients by the Acceptable Mismatch Program Frans H. J. Claas, 1 Axel Rahmel, 2 and IIias I. N. Doxiadis 1 Even in this era of efficient immunosuppression,
More informationMary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014
Solid Organ Transplantation How the Lab Contributes to Improved Patient Outcomes Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT 4th April 2014 Solid Organ Transplantation
More informationBasel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
More informationAuthor(s) Umemura, Kenji; Sugihara, Osamu; Ka. Citation Journal of Wood Science (2013), 59(
Title Investigation of a new natural adhe and sucrose for particleboard Author(s) Umemura, Kenji; Sugihara, Osamu; Ka Citation Journal of Wood Science (2013), 59( Issue Date 2013-06 URL http://hdl.handle.net/2433/189837
More informationGi-Won Song ABO Incompatability in Liver Transplantation
ABO Incompatability in Liver Transplantation http://dx.doi.org/10.7599/hmr.2014.34.4.202 pissn 1738-429X eissn 2234-4446 Gi-Won Song Department of Surgery, Division of Liver Transplantation and HepatobiliarySurgry,
More informationTreatment with Immunoglobulin Improves Outcome for Pediatric Liver Transplant Recipients
LIVER TRANSPLANTATION 15:1564-1569, 2009 ORIGINAL ARTICLE Treatment with Immunoglobulin Improves Outcome for Pediatric Liver Transplant Recipients John C. Bucuvalas, and Ravinder Anand, 2 Studies of Pediatric
More informationLiving-Donor Kidney Transplant in T-Cell and B-Cell Flow Cytometry Crossmatch-Positive Patients
ARTICLe Living-Donor Kidney Transplant in T-Cell and B-Cell Flow Cytometry Crossmatch-Positive Patients Soushi Terasaka, 1 Hidehisa Kitada, 1,3 Yasuhiro Okabe, 1 Sayako Kawanami, 1 Hiroshi Noguchi, 1 Kyoko
More informationABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab
American Journal of Transplantation 2016; 16: 157 170 Wiley Periodicals Inc. C Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13444
More informationDE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
More informationCombined Liver and Kidney Transplantation with Particular Reference to Positive Cytotoxic Crossmatches
T.E. Starzl. A. Tzakis. L. Makowka. J. Fung. G. Klintmalm. S. Todo. R. Gordon. and M. Griffin 40 Combined Liver and Kidney Transplantation with Particular Reference to Positive Cytotoxic Crossmatches SUMMARY
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationResearch Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival
Clinical and Developmental Immunology Volume 2013, Article ID 828201, 5 pages http://dx.doi.org/10.1155/2013/828201 Research Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect
More informationA POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION
THE NEW KIDNEY ALLOCATION SYSTEM: A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION Paul Warner, PhD, D(ABHI) Director, HLA/Immunogenetics Laboratory Bloodworks Northwest Seattle, Washington Disclosure
More informationDesensitization for solid organ and hematopoietic stem cell transplantation
Andrea A. Zachary Mary S. Leffell Desensitization for solid organ and hematopoietic stem cell transplantation Authors address Andrea A. 1 Zachary, Mary S. Leffell 1 1 Department of Medicine, Division of
More informationPulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationImpact of ultrasound examination shortly after kidney transplantation
Eur Surg (2017) 49:140 144 DOI 10.1007/s10353-017-0467-z Impact of ultrasound examination shortly after kidney transplantation Christoph Schwarz Jakob Mühlbacher Georg A. Böhmig Marin Purtic Eleonore Pablik
More informationCitation Transplantation Proceedings, 47(3),
NAOSITE: Nagasaki University's Ac Title Author(s) Hybrid Procedure in Living Donor Li Soyama, Akihiko; Takatsuki, Mitsuhi Tomohiko; Kitasato, Amane; Kinoshit Baimakhanov, Zhassulan; Kuroki, Tam Citation
More information